Editas Medicine Inc EDIT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 10:53 AM EDT
5.78quote price arrow down-0.24 (-3.99%)
Volume
559,844
52 week range
4.91 - 11.91
Loading...
  • Open6.01
  • Day High6.05
  • Day Low5.66
  • Prev Close6.02
  • 52 Week High11.91
  • 52 Week High Date06/14/23
  • 52 Week Low4.91
  • 52 Week Low Date05/08/24

Key Stats

  • Market Cap475.335M
  • Shares Out82.24M
  • 10 Day Average Volume1.92M
  • Dividend-
  • Dividend Yield-
  • Beta2.06
  • YTD % Change-42.84

KEY STATS

  • Open6.01
  • Day High6.05
  • Day Low5.66
  • Prev Close6.02
  • 52 Week High11.91
  • 52 Week High Date06/14/23
  • 52 Week Low4.91
  • 52 Week Low Date05/08/24
  • Market Cap475.335M
  • Shares Out82.24M
  • 10 Day Average Volume1.92M
  • Dividend-
  • Dividend Yield-
  • Beta2.06
  • YTD % Change-42.84

RATIOS/PROFITABILITY

  • EPS (TTM)-2.10
  • P/E (TTM)-2.75
  • Fwd P/E (NTM)-2.21
  • EBITDA (TTM)-179.281M
  • ROE (TTM)-54.30%
  • Revenue (TTM)69.407M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-239.36%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date07/31/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Editas Medicine Inc

 

Profile

MORE
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1)...
Emma Reeve
Independent Chairman of the Board
Gilmore O Neill
President, Chief Executive Officer, Director
Erick Lucera
Chief Financial Officer, Executive Vice President
Linda Burkly Ph.D.
Executive Vice President, Chief Scientific Officer
Address
11 Hurley St
Cambridge, MA
02141-2110
United States

Top Peers

SYMBOLLASTCHG%CHG
TBPH
Theravance Biopharma Inc
8.57-0.41-4.57%
ADCT
ADC Therapeutics SA
3.65-0.02-0.54%
URGN
Urogen Pharma Ltd
13.11-0.20-1.50%
YMAB
Y-mAbs Therapeutics Inc
12.87+0.02+0.16%
ALEC
Alector Inc
5.43-0.01-0.18%